CL2017000625A1 - Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos - Google Patents
Composiciones de glicoconjugado inmunogénico/terapéutico y sus usosInfo
- Publication number
- CL2017000625A1 CL2017000625A1 CL2017000625A CL2017000625A CL2017000625A1 CL 2017000625 A1 CL2017000625 A1 CL 2017000625A1 CL 2017000625 A CL2017000625 A CL 2017000625A CL 2017000625 A CL2017000625 A CL 2017000625A CL 2017000625 A1 CL2017000625 A1 CL 2017000625A1
- Authority
- CL
- Chile
- Prior art keywords
- therapeutic
- disease
- klh
- obi
- severity
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000009429 distress Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001173—Globo-H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>LA PRESENTE DESCRIPCIÓN INCLUYE COMPOSICIONES INMUNOGÉNICAS/TERAPÉUTICAS QUE INCLUYEN GLICOCONJUGADOS GLOBO H-KLH (OBI-822) Y/O ADYUVANTES TERAPÉUTICOS (OBI-821/OBI-834) ASÍ COMO TAMBIÉN, MÉTODOS PARA PREPARARLOS Y UTILIZARLOS PARA TRATAR ENFERMEDADES PROLIFERATIVAS COMO EL CÁNCER. ESTOS CONJUGADOS TERAPÉUTICOS INCLUYEN UN ANTÍGENO LIGADO A UN VEHÍCULO. EN PARTICULAR, LOS CONJUGADOS TERAPÉUTICOS INCLUYEN UNA PORCIÓN GLOBO H Y UNA PORCIÓN KLH Y/O UNA SUBUNIDAD DE PORCIÓN KLH DERIVADA OPCIONALMENTE LIGADA MEDIANTE UN LIGANTE. LAS COMPOSICIONES TERAPÉUTICAS ESTÁN EN PARTE CONCEBIDAS PARA ACTUAR COMO VACUNAS CONTRA EL CÁNCER PARA ESTIMULAR LA CAPACIDAD NATURAL QUE TIENE EL CUERPO DE PROTEGERSE A SÍ MISMO, A TRAVÉS DEL SISTEMA INMUNOLÓGICO, DE LOS PELIGROS IMPUESTOS POR LAS CÉLULAS DAÑADAS O ANORMALES COMO LAS CÉLULAS CANCERÍGENAS. LA RESPUESTA INMUNOLÓGICA EJEMPLAR PUEDE SER CARACTERIZADA MEDIANTE LA REDUCCIÓN DE LA SEVERIDAD DE LA ENFERMEDAD, INCLUSO PERO SIN LIMITARSE A LA PREVENCIÓN DE LA ENFERMEDAD, INCLUSO EN EL INICIO DE LA ENFERMEDAD, DISMINUCIÓN DE LA SEVERIDAD DE LOS SÍNTOMAS, MORBILIDAD DISMINUIDA Y MORTALIDAD RETARDADA.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050567P | 2014-09-15 | 2014-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000625A1 true CL2017000625A1 (es) | 2018-02-02 |
Family
ID=55533765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000625A CL2017000625A1 (es) | 2014-09-15 | 2017-03-14 | Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160339089A1 (es) |
| EP (1) | EP3193919B1 (es) |
| JP (1) | JP6774941B2 (es) |
| KR (2) | KR20230109783A (es) |
| CN (1) | CN107427564A (es) |
| AR (1) | AR101871A1 (es) |
| AU (1) | AU2015317889B2 (es) |
| BR (1) | BR112017005120B1 (es) |
| CA (1) | CA2961522A1 (es) |
| CL (1) | CL2017000625A1 (es) |
| ES (1) | ES2797747T3 (es) |
| IL (1) | IL251120B (es) |
| MY (1) | MY188880A (es) |
| PH (1) | PH12017500478A1 (es) |
| RU (1) | RU2720295C2 (es) |
| SG (1) | SG11201702037SA (es) |
| TW (1) | TWI726850B (es) |
| WO (1) | WO2016044326A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180050339A (ko) | 2015-09-04 | 2018-05-14 | 오비아이 파머 인코퍼레이티드 | 글리칸 어레이 및 사용 방법 |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| WO2017172990A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| IL262296B1 (en) * | 2016-04-22 | 2024-05-01 | Obi Pharma Inc | Cancer immunotherapy using immune activation or immune modulation by Globo-series antigens |
| KR20230117482A (ko) | 2016-07-27 | 2023-08-08 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| AU2017361549B2 (en) | 2016-11-21 | 2023-12-21 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| WO2019217951A1 (en) * | 2018-05-11 | 2019-11-14 | Obi Pharma Inc. | Method for predicting human immune response |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544952B1 (en) * | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
| US7854934B2 (en) * | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| US7824687B2 (en) * | 1999-08-20 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof |
| JP2005526692A (ja) * | 2001-08-14 | 2005-09-08 | ビオミラ，インコーポレーテッド | 炭水化物ハプテンの免疫原共役体および凝集タンパク質キャリヤ |
| AU2009268937A1 (en) * | 2008-06-16 | 2010-01-14 | Aj Park | Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment |
| CN105535955B (zh) * | 2009-06-16 | 2019-04-23 | 中央研究院 | Globo h及含新颖糖脂质佐剂的相关抗癌疫苗 |
| EP2500035A1 (en) * | 2011-03-15 | 2012-09-19 | Icon Genetics GmbH | Pharmaceutical formulation containing immunglobulin |
| CA3044471C (en) * | 2013-01-04 | 2021-05-11 | Obi Pharma, Inc. | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
| WO2015159118A2 (en) * | 2013-09-17 | 2015-10-22 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
-
2015
- 2015-09-15 WO PCT/US2015/050270 patent/WO2016044326A1/en active Application Filing
- 2015-09-15 TW TW104130500A patent/TWI726850B/zh active
- 2015-09-15 AR ARP150102941A patent/AR101871A1/es unknown
- 2015-09-15 BR BR112017005120-6A patent/BR112017005120B1/pt active IP Right Grant
- 2015-09-15 CA CA2961522A patent/CA2961522A1/en active Pending
- 2015-09-15 AU AU2015317889A patent/AU2015317889B2/en active Active
- 2015-09-15 KR KR1020237023433A patent/KR20230109783A/ko active IP Right Grant
- 2015-09-15 EP EP15842660.1A patent/EP3193919B1/en active Active
- 2015-09-15 ES ES15842660T patent/ES2797747T3/es active Active
- 2015-09-15 JP JP2017514552A patent/JP6774941B2/ja active Active
- 2015-09-15 SG SG11201702037SA patent/SG11201702037SA/en unknown
- 2015-09-15 KR KR1020177009879A patent/KR102679516B1/ko active IP Right Grant
- 2015-09-15 US US14/855,260 patent/US20160339089A1/en active Pending
- 2015-09-15 RU RU2017112982A patent/RU2720295C2/ru active
- 2015-09-15 MY MYPI2017000385A patent/MY188880A/en unknown
- 2015-09-15 CN CN201580062962.2A patent/CN107427564A/zh active Pending
-
2017
- 2017-03-13 IL IL251120A patent/IL251120B/en active IP Right Grant
- 2017-03-13 PH PH12017500478A patent/PH12017500478A1/en unknown
- 2017-03-14 CL CL2017000625A patent/CL2017000625A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107427564A (zh) | 2017-12-01 |
| EP3193919B1 (en) | 2020-04-08 |
| AU2015317889B2 (en) | 2021-06-03 |
| RU2720295C2 (ru) | 2020-04-28 |
| AU2015317889A1 (en) | 2017-04-13 |
| JP2017532310A (ja) | 2017-11-02 |
| KR20230109783A (ko) | 2023-07-20 |
| EP3193919A4 (en) | 2018-04-18 |
| KR102679516B1 (ko) | 2024-07-02 |
| JP6774941B2 (ja) | 2020-10-28 |
| KR20170090405A (ko) | 2017-08-07 |
| US20160339089A1 (en) | 2016-11-24 |
| IL251120A0 (en) | 2017-04-30 |
| IL251120B (en) | 2021-05-31 |
| RU2017112982A3 (es) | 2019-04-24 |
| BR112017005120A2 (pt) | 2018-01-23 |
| ES2797747T3 (es) | 2020-12-03 |
| PH12017500478A1 (en) | 2017-07-10 |
| TW201628646A (zh) | 2016-08-16 |
| MY188880A (en) | 2022-01-12 |
| TWI726850B (zh) | 2021-05-11 |
| AR101871A1 (es) | 2017-01-18 |
| WO2016044326A9 (en) | 2017-05-11 |
| BR112017005120B1 (pt) | 2021-01-05 |
| CA2961522A1 (en) | 2016-03-24 |
| EP3193919A1 (en) | 2017-07-26 |
| WO2016044326A1 (en) | 2016-03-24 |
| SG11201702037SA (en) | 2017-04-27 |
| RU2017112982A (ru) | 2018-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000625A1 (es) | Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| AR097661A1 (es) | Composiciones de una vacuna de carbohidratos para inducir respuestas inmunológicas y sus usos en el tratamiento del cáncer | |
| WO2015168379A3 (en) | Combination vaccine devices and methods of killing cancer cells | |
| MX2022007522A (es) | Anticuerpos anti-cd27. | |
| MX2017006408A (es) | Linfocitos t gamma delta modificados geneticamente. | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| AR104664A1 (es) | Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6) | |
| MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
| MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
| MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| MX2023001540A (es) | Vacunas contra el cancer y metodos de tratamiento que las utilizan. | |
| CL2017001135A1 (es) | Anticuerpos mejorados contra il-6 | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| GT201700194A (es) | Formulación de combinación de tesofensina y betabloqueante | |
| NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
| CL2016002469A1 (es) | Sulfamidasa modificada y su producción | |
| UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
| ES2503516R1 (es) | Complejo inmunogénico para vacunación y método de obtención | |
| BR112017002206A2 (pt) | peptídeo derivado de koc1 e vacina incluindo o mesmo | |
| NI201800105A (es) | Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos. | |
| BR112017002193A2 (pt) | peptídeo derivado de urlc10 e vacina contendo o mesmo | |
| CL2018002004A1 (es) | Conjugado amiloide y usos y procedimientos del mismo | |
| UY36860A (es) | Vacunas recombinantes contra el calicivirus felino (fcv) y sus usos |